Top-News
  • Depot
  • Watchlist
  • Glocke

    • Savara News

    3,72 € 0,00% +0,00 €
    08:00:19 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DQ2B
    ISIN: US8051111016
    US-Symbol: SVRA
    Typ: Aktie

    Savara News

    21.11.23 - Businesswire
    Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a ...
    09.11.23 - Businesswire
    Savara Reports Third Quarter Financial Results and Provides Business Update
    Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending ...
    08.11.23 - Businesswire
    Savara to Present at the Jefferies London Healthcare Conference
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a ...
    06.10.23 - Businesswire
    Savara Announces New Employment Inducement Grant
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new ...
    17.03.21 - PR Newswire
    Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
    Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara? PR Newswire
    16.03.21 - PR Newswire
    Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?
    Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health? PR Newswire
    02.04.19 - ACCESSWIRE
    Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
    AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at ...
    13.03.19 - ACCESSWIRE
    Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
    On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019
    06.03.19 - ACCESSWIRE
    Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
    AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 ...
    04.03.19 - ACCESSWIRE
    Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
    AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob ...
    11.07.17 - PR Newswire
    Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
    Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension Aironite Significantly Lowered ...
    20.06.17 - PR Newswire
    Savara Set To Join Russell Microcap® Index
    Savara Set To Join Russell Microcap® Index PR Newswire
    05.06.17 - PR Newswire
    Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
    Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th PR Newswire
    02.06.17 - PR Newswire
    Savara Announces Pricing Of Public Offering Of Common Stock
    Savara Announces Pricing Of Public Offering Of Common Stock PR Newswire
    01.06.17 - PR Newswire
    Savara Announces Proposed Public Offering Of Common Stock
    Savara Announces Proposed Public Offering Of Common Stock PR Newswire
    10.05.17 - PR Newswire
    Savara Announces Expedited U.S. Molgradex Development Strategy
    Savara Announces Expedited U.S. Molgradex Development Strategy Ongoing IMPALA Study to be Expanded to Serve as Global Pivotal Study for Registration PR Newswire
    08.05.17 - PR Newswire
    Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc
    Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc PR Newswire
    01.05.17 - PR Newswire
    Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank
    Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank PR Newswire
    28.04.17 - PR Newswire
    Savara Announces Closing Of Merger With Mast Therapeutics
    Savara Announces Closing Of Merger With Mast Therapeutics Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol "SVRA" Conference Call ...
    27.04.17 - PR Newswire
    Savara Announces Closing Of Merger With Mast Therapeutics
    Savara Announces Closing Of Merger With Mast Therapeutics Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol "SVRA" Conference Call ...

    Newssuche

    Videos

    06.12.23 +20,61%
    Technical Trading: Top Chance in Baumwolle
    Cotton Long Typ: Turbo Optionsschein WKN: VX1LGX Hebel: 5,34 Laufzeit: OpenEnd Einstieg: Market ... Mehr »